Helen McShane

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
  2. ncbi request reprint Tuberculosis vaccines: current status and future prospects
    Helen Fletcher
    University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    Expert Opin Emerg Drugs 11:207-15. 2006
  3. doi request reprint A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
    Helen McShane
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK Electronic address
    Tuberculosis (Edinb) 94:105-10. 2014
  4. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
  5. pmc Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining
    Steven G Smith
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    BMC Immunol 11:35. 2010
  6. ncbi request reprint Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Tuberculosis (Edinb) 85:47-52. 2005
  7. ncbi request reprint Co-infection with HIV and TB: double trouble
    Helen McShane
    Harrison Clinic, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Int J STD AIDS 16:95-100; quiz 101. 2005
  8. ncbi request reprint Prime-boost immunisation strategies for tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Microbes Infect 7:962-7. 2005
  9. doi request reprint Vaccine strategies against tuberculosis
    Helen McShane
    The Jenner Institute, University of Oxford, Oxford, UK
    Swiss Med Wkly 139:156-60. 2009
  10. ncbi request reprint Need for more TB vaccine field sites
    Helen McShane
    The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ
    Indian J Exp Biol 47:445-6. 2009

Detail Information

Publications61

  1. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...
  2. ncbi request reprint Tuberculosis vaccines: current status and future prospects
    Helen Fletcher
    University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    Expert Opin Emerg Drugs 11:207-15. 2006
    ..Research efforts that focus on reducing the cost and risk of conducting clinical trials will be of direct benefit to tuberculosis vaccine development...
  3. doi request reprint A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
    Helen McShane
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK Electronic address
    Tuberculosis (Edinb) 94:105-10. 2014
    ..Here we review the efficacy in animal models of the MVA85A candidate vaccine in light of recent human efficacy data and propose refinements to the preclinical models with the aim of increasing their predictive value for human efficacy. ..
  4. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
    ..A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants...
  5. pmc Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining
    Steven G Smith
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    BMC Immunol 11:35. 2010
    ..The aim of this study was to identify which cytokines and lymphocyte populations characterise the peripheral blood cellular immune response following BCG vaccination...
  6. ncbi request reprint Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Tuberculosis (Edinb) 85:47-52. 2005
    ..MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed...
  7. ncbi request reprint Co-infection with HIV and TB: double trouble
    Helen McShane
    Harrison Clinic, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Int J STD AIDS 16:95-100; quiz 101. 2005
    ..Indications for chemoprophylaxis and vaccination against TB are reviewed...
  8. ncbi request reprint Prime-boost immunisation strategies for tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Microbes Infect 7:962-7. 2005
    ..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained...
  9. doi request reprint Vaccine strategies against tuberculosis
    Helen McShane
    The Jenner Institute, University of Oxford, Oxford, UK
    Swiss Med Wkly 139:156-60. 2009
    ..In addition, the cellular immune response induced is highly polyfunctional. The protective efficacy of MVA85A will be evaluated in a Phase IIb trial commencing in early 2009 in South African infants...
  10. ncbi request reprint Need for more TB vaccine field sites
    Helen McShane
    The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ
    Indian J Exp Biol 47:445-6. 2009
    ..There is currently inadequate capacity within high-burden TB countries to conduct these essential trials. We need to invest now to expand current capacity if we are to reduce the time taken to develop new vaccines...
  11. pmc Tuberculosis vaccines: beyond bacille Calmette-Guerin
    Helen McShane
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2782-9. 2011
    ..This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing...
  12. ncbi request reprint Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  13. ncbi request reprint Developing an improved vaccine against tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Expert Rev Vaccines 3:299-306. 2004
    ..The issues surrounding the progression of the most promising candidates into Phase I clinical trials are also discussed...
  14. pmc Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
    H McShane
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Infect Immun 69:681-6. 2001
    ....
  15. pmc Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A
    Helen McShane
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Infect Immun 70:1623-6. 2002
    ....
  16. ncbi request reprint Prime-boost immunization strategies for infectious diseases
    Helen McShane
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, UK
    Curr Opin Mol Ther 4:23-7. 2002
    ..Prime-boost immunization strategies involve using two different vaccines, each encoding the same antigen, some weeks apart. Such strategies have been shown to enhance cellular immunity in several different animal and disease models...
  17. pmc Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice
    Emily K Forbes
    The Jenner Institute, University of Oxford, Headington, Oxford, United Kingdom
    J Immunol 181:4955-64. 2008
    ..Successful immunization regimes appear to induce Ag-specific cells with abundant intracellular cytokine staining...
  18. pmc Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
    Kathryn T Whelan
    Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 4:e5934. 2009
    ....
  19. pmc Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials
    Ansar A Pathan
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 2:e1052. 2007
    ....
  20. pmc Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
    Elma Z Tchilian
    The Jenner Institute, Oxford University, ORCRB, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Infect Immun 77:622-31. 2009
    ..This emphasizes the need for new biomarkers for the evaluation of TB vaccine efficacy...
  21. doi request reprint A comparison of IFNgamma detection methods used in tuberculosis vaccine trials
    Natalie E R Beveridge
    Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
    Tuberculosis (Edinb) 88:631-40. 2008
    ..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved...
  22. ncbi request reprint Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara
    Nilu P Goonetilleke
    Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:1602-9. 2003
    ..These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis...
  23. pmc Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding
    Eung Jun Im
    Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
    J Virol 81:9408-18. 2007
    ....
  24. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...
  25. pmc Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
    Ansar A Pathan
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Vaccine 30:5616-24. 2012
    ....
  26. pmc Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial
    Rosalind Rowland
    Jenner Institute University of Oxford, Oxford, UK
    Hum Vaccin Immunother 9:50-62. 2013
    ..We hypothesize that FP85A induced anti-FP9 IgG antibodies with cross-reactivity for MVA85A, which may have mediated inhibition of the immune response to subsequent MVA85A. ClinicalTrials.gov identification number: NCT00653770...
  27. pmc Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1
    Helen A Fletcher
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 26:5269-75. 2008
    ..This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines...
  28. pmc Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A
    Kristin L Griffiths
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    PLoS ONE 6:e23463. 2011
    ..These results suggest a relationship between extracellular ATP and effector responses and unveil a possible pathway that could be targeted during vaccine design...
  29. doi request reprint Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
    Joel Meyer
    Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    Vaccine 31:1026-33. 2013
    ..To date, intramuscular delivery has not been evaluated. Skin and muscle have distinct anatomical and immunological properties which could impact upon vaccine-mediated cellular immunity...
  30. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
    ..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care...
  31. pmc Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A
    Magali Matsumiya
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 8:e67922. 2013
    ....
  32. pmc Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
    Gareth Betts
    Nuffield Department of Surgery, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 7:e50447. 2012
    ..Furthermore, an insight is provided to the impact on vaccine immunogenicity from altering vaccination methods to reduce the logistical demands of using separate vaccine preparations in the field...
  33. pmc A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin
    Angela M Minassian
    The Jenner Institute, University of Oxford, UK
    J Infect Dis 205:1035-42. 2012
    ..In vivo antimycobacterial immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination as a surrogate for M. tuberculosis infection...
  34. pmc Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  35. doi request reprint Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
    Stephanie A Harris
    Jenner Institute, University of Oxford, Oxford, United Kingdom
    J Infect Dis 209:1259-68. 2014
    ..Clinical Trials Registration NCT01194180. ..
  36. ncbi request reprint Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Inese Cebere
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Vaccine 24:417-25. 2006
    ..HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies...
  37. pmc Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses
    Anna M Checkley
    The Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Oxford, United Kingdom
    PLoS ONE 6:e26434. 2011
    ..These early findings may provide a basis for characterising exposure to NTM at a population level, which has applications in the field of TB vaccine design as well as in the development of diagnostic tests...
  38. doi request reprint Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)
    Leanne Marsay
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Tuberculosis (Edinb) 93:551-7. 2013
    ..Further investigation into whether the BACTEC MGIA can be used as a surrogate of protection in humans and preclinical animal models is now warranted. ..
  39. ncbi request reprint Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART
    Rebecca Sutherland
    MRC Human Immunology Unit, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    AIDS 20:821-9. 2006
    ..To determine whether long-term HAART in chronic HIV-1 infection restores fully functional Mycobacterium tuberculosis (MTB)-specific CD4 T-cell responses...
  40. pmc Dual neonate vaccine platform against HIV-1 and M. tuberculosis
    Richard Hopkins
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e20067. 2011
    ..tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life...
  41. pmc Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy
    Angela M Minassian
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e19840. 2011
    ..tb challenge. Translation of these findings to a human BCG challenge model could enable more rapid assessment and down selection of candidate TB vaccines and ultimately the identification of an immune correlate of protection...
  42. pmc Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
    Kristin L Griffiths
    Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 8:e78312. 2013
    ..This observed increase in IL-17 in the lungs has no adverse effect on lung pathology following M.tb challenge, indicating that IL-17 can safely be boosted in murine lungs in a vaccine/M.tb challenge setting. ..
  43. pmc Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG
    Helen A Fletcher
    Jenner Institute, University of Oxford, Oxford, United Kingdom
    Clin Vaccine Immunol 20:1683-9. 2013
    ....
  44. doi request reprint The next 10 years for tuberculosis vaccines: do we have the right plans in place?
    Joel Meyer
    The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK
    Expert Rev Vaccines 12:443-51. 2013
    ..Moreover, the increasing pace, extent and coordination of global research efforts in TB promises to broaden understanding and inform the next generation of vaccine candidates against TB as well as related globally important pathogens...
  45. pmc A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
    Angela M Minassian
    The Jenner Institute, Oxford University, Oxford, UK
    BMJ Open 1:e000223. 2011
    ..Conclusion MVA85A is safe and immunogenic in healthy adults infected with HIV. Further safety and efficacy evaluation of this candidate vaccine in TB- and HIV-endemic areas is merited...
  46. ncbi request reprint CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages
    Roger H Brookes
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, GB
    Eur J Immunol 33:3293-302. 2003
    ..These data identify a previously unrecognized CD8(+) T cell-mediated mechanism used to control an intracellular infection of macrophages...
  47. pmc Tuberculosis vaccines in clinical trials
    Rosalind Rowland
    The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK
    Expert Rev Vaccines 10:645-58. 2011
    ..There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen...
  48. ncbi request reprint Tuberculosis vaccines: present and future
    Angela M Minassian
    Clinical Research Fellow, The Jenner Institute, University of Oxford, Old Road Campus Research Building, Level 2, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Expert Rev Respir Med 2:721-38. 2008
    ....
  49. ncbi request reprint Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells
    A Lalvani
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Respir Crit Care Med 163:824-8. 2001
    ..tuberculosis infection and BCG vaccination. This capability may facilitate tuberculosis control in nonendemic regions...
  50. ncbi request reprint Efficacy of follow-up and contact tracing of women who test positive for genital tract chlamydia trachomatis prior to pregnancy termination
    P T Ayuk
    Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford, UK
    J Obstet Gynaecol 24:687-9. 2004
    ..003). In conclusion, follow-up and contact-tracing of women who screen positive for genital tract C. trachomatis was incomplete. This may substantially compromise the cost-effectiveness of a screen-and-treat programme...
  51. pmc Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis
    C Sander
    University of Oxford, CCVTM, Churchill Hospital, Oxford, UK
    Clin Exp Immunol 147:401-11. 2007
    ..Here, the steps involved in the development and evaluation of TB vaccines will be discussed, including description of the most frequently used animal models and the processes involved in advancing vaccines to phase III trials...
  52. pmc Incidental diagnosis in healthy clinical trial subjects
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Drive, OX3 7LJ, United Kingdom
    Clin Transl Sci 5:348-50. 2012
    ..02 χ(2) for trend) but not females (p= 0.82). These data will assist those planning and conducting phase I/II vaccine trials in healthy volunteers, and importantly should strengthen the informed consent of future trial participants...
  53. doi request reprint Tuberculosis vaccines: progress and challenges
    Anna M Checkley
    Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
    Trends Pharmacol Sci 32:601-6. 2011
    ..Following this, large efficacy trials are undertaken, which face the daunting challenges of cost, logistics and trial site capacity...
  54. pmc Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs
    A Williams
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
    Infect Immun 73:3814-6. 2005
    ....
  55. ncbi request reprint Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment
    A A Pathan
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 167:5217-25. 2001
    ..tuberculosis in vivo. Such findings may assist in the design and evaluation of novel tuberculosis vaccine candidates...
  56. pmc Susceptibility to tuberculosis--the importance of the pathogen as well as the host
    H McShane
    Nuffield Department of Medicine, University of Oxford, Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
    Clin Exp Immunol 133:20-1. 2003
  57. ncbi request reprint Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design
    Hannah B Ibanga
    MRC Laboratories, Fajara, The Gambia
    Lancet Infect Dis 6:522-8. 2006
    ..These issues are highly relevant to early clinical trials with all new tuberculosis vaccines in the developing world...
  58. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
    Tony Hawkridge
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    J Infect Dis 198:544-52. 2008
    ..We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic...
  59. ncbi request reprint A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
    Matilu Mwau
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford OX3 9DS, UK
    J Gen Virol 85:911-9. 2004
    ..These results are very encouraging and justify further vaccine development...
  60. ncbi request reprint Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis
    Ann Williams
    Health Protection Agency, Porton Down, Salisbury SP4 OJG, UK
    Tuberculosis (Edinb) 85:29-38. 2005
    ..A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A...
  61. ncbi request reprint The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo
    Martin O C Ota
    Bacterial Diseases Programme, Medical Research Council, P O Box 273, Banjul, Gambia
    Vaccine 25:8861-7. 2007
    ..We conclude that BCG is immunogenic, but this effector response is short-lived and can be limited in higher pre-existing anti-mycobacterial immunity, suggesting a possible threshold beyond which BCG immunogenicity is inhibited...